The Bioavailability and Pharmacokinetics of Silymarin SMEDDS Formulation Study in Healthy Thai Volunteers

© 2018 Chuleegone Sornsuvit et al. The present study aimed to determine the pharmacokinetic parameters and bioavailability of silymarin 140 mg SMEDDS formulation. An open-label, single-dose pharmacokinetic study was conducted. Twelve healthy volunteers were included in the study. After the volunteer...

全面介紹

Saved in:
書目詳細資料
Main Authors: Chuleegone Sornsuvit, Darunee Hongwiset, Songwut Yotsawimonwat, Manatchaya Toonkum, Satawat Thongsawat, Wandee Taesotikul
格式: 雜誌
出版: 2018
主題:
在線閱讀:https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85051031069&origin=inward
http://cmuir.cmu.ac.th/jspui/handle/6653943832/59028
標簽: 添加標簽
沒有標簽, 成為第一個標記此記錄!
實物特徵
總結:© 2018 Chuleegone Sornsuvit et al. The present study aimed to determine the pharmacokinetic parameters and bioavailability of silymarin 140 mg SMEDDS formulation. An open-label, single-dose pharmacokinetic study was conducted. Twelve healthy volunteers were included in the study. After the volunteers had fasted overnight for 10 h, a single-dose generic silymarin 140 mg SMEDDS soft capsule was administered. Then 10 ml blood samples were taken at 0.0, 0.25, 0.50, 0.75, 1.0, 1.33, 1.67, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, and 12.0 h. The plasma silybin concentrations were analyzed using validated LC-MS/MS. The pharmacokinetic parameters were analyzed and calculated. The pharmacokinetic parameters were calculated after silymarin had been administered as a single capsule. The mean (range) Cmaxwas 812.43 (259.47-1505.47) ng/ml at 0.80 (0.25-1.67) h (tmax). The mean (range) AUC0-tand AUC0-infwere 658.80 (268.29-1045.01) ng.h/ml and 676.98 (274.10-1050.96) ng.h/ml, respectively. The mean keand t1/2were 0.5386 h-1and 1.91 h, respectively. The silymarin SMEDDS formulation soft capsule showed rapid absorption and high oral bioavailability.